PSK Pharma seeks to become leading Russian drugmaker

PSK Pharma, a Russian drugmaker that is part of the local Rus Biopharm Group, is looking to become one of the leading pharmaceutical companies in Russia in the coming years to come, achieving this by a significant increase of its output and expansion of its range, reports The Pharma Letter’s local correspondent.

Evgenia Shapiro, general director of PSK Pharma, said in an interview with the Russian Kommersant business paper, as part of the company’s plans is focusing on the development and production of technologically sophisticated drugs, particularly those from the list of vital and essential. Implementation of these plans will be part of the existing state policy of import substitution in the Russian pharmaceutical sector, which is implemented by the local government.

Ms Shapiro comments: “Currently our portfolio includes almost 60 drugs, 13 of them are the first Russian generics. In a number of positions, we have completely replaced foreign original drugs. The goal is to double our portfolio over the next two years.”